Who are LBL-007's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brukinsa, Calquence, Acalabrutinib capsule, MGd, (G) BQ-L14, Ibrutinib (Maintenance).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lbl-007.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LBL-007 — Competitive Intelligence Brief

LBL-007 (LBL-007) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bruton's tyrosine kinase (BTK) inhibitor. Area: Oncology.

phase 3 Bruton's tyrosine kinase (BTK) inhibitor BTK Oncology Small molecule Live · refreshed every 30 min

Target snapshot

LBL-007 (LBL-007) — BeiGene. LBL-007 is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell and myeloid cell activation in hematologic malignancies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LBL-007 TARGET	LBL-007	BeiGene	phase 3	Bruton's tyrosine kinase (BTK) inhibitor	BTK
Brukinsa	BGB-3111	Beigene Usa Inc	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2019-01-01
Calquence	ACALABRUTINIB	AstraZeneca	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2017-01-01
Acalabrutinib capsule	Acalabrutinib capsule	AstraZeneca	marketed	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
MGd	MGd	Pharmacyclics LLC.	marketed	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
(G) BQ-L14	(G) BQ-L14	National Taiwan University Hospital	marketed	BTK inhibitor	BTK
Ibrutinib (Maintenance)	Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman)	phase 3	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-04-22 — Brukinsa · 10570139 · US
2034-04-22 — Brukinsa · 11142528 · US
2034-04-22 — Brukinsa · 9447106 · US
2037-08-15 — Brukinsa · 11591340 · US
2037-08-15 — Brukinsa · 10927117 · US

Sponsor landscape (Bruton's tyrosine kinase (BTK) inhibitor class)

AstraZeneca · 2 drugs in this class
Pharmacyclics LLC. · 2 drugs in this class
Prof. Dr. M. Dreyling (co-chairman) · 2 drugs in this class
BeiGene · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LBL-007 — Competitive Intelligence Brief. https://druglandscape.com/ci/lbl-007. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab